Genentech pulls Raptiva from the U.S. market. Risk/benefit ratio got too dicey. AstraZeneca gets a limited approval for Seroquel as add-on treatment for depression. Layoffs + executive raises. Works …
Today’s Top Three in Pharma 022009
Genentech's Raptiva: Trouble - The FDA said today that patients taking the Genentech drug Raptiva are at risk of developing a potentially fatal condition known as PML, or progressive multifocal …